Research programme: therapeutic agents - Celltech Group/Medarex/Genmab

Drug Profile

Research programme: therapeutic agents - Celltech Group/Medarex/Genmab

Alternative Names: Breast cancer research programme - Celltech Group/Medarex; HuMax-Cancer; MDX 067; MDX-OGS 001; OGS-MDX 067; Research programme: breast cancer - Celltech Group/Medarex

Latest Information Update: 03 May 2007

Price : $50

At a glance

  • Originator Genmab; Medarex; UCB
  • Developer UCB
  • Class Monoclonal antibodies
  • Mechanism of Action Heparanase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 03 May 2007 Discontinued - Preclinical for Breast cancer in England (unspecified route)
  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
  • 12 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top